EVOLUTION AT MERCK - INVENTING FOR LIFE

ESTABLISHING LEADERSHIP IN GROWING ONCOLOGY MARKET • Largest I-O clinical development • • program in the industry • Sizable long-term opportunity in new tumor types, including TNBC and prostate cancer Broad combination program with Lynparza, Lenvima and others Significant long-term opportunities in adjuvant / neoadjuvant settings $300 Worldwide oncology sales ($B) $250 ■IO/PARP/VEGF/R ■Cytotoxic, CD20, CDK, BTK, CD38 $200 ■■Hormonal, EGFR, HER 2/3, Other, Other Targeted, Next Wave $150 $100 $50 $0 Source: EvaluatePharma 2019 Well positioned to grow faster than the market 2028 MERCK H Mike Nally I INVENTING FOR LIFE 59

View entire presentation